ArticleInternational journal of clinical and experimental pathology2014
Increased IL-12 and decreased IL-33 serum levels are associated with increased Th1 and suppressed Th2 cytokine profile in patients with diabetic nephropathy (CURES-134).
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Increased Circulating Interleukin Concentrations in Type 2 Diabetes: A Systematic Review and Meta-Analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Pooled it
- Circulating interleukin-33 levels in obesity and type 2 diabetes: a systematic review and meta-analysis.American journal of physiology. Endocrinology and metabolism · 2024Pooled it
- Identification of diagnostic markers for diabetic kidney disease by weighted gene co‑expression network analysis and machine learning.International journal of molecular medicine · 2026Article
- Morphological and Biochemical Insights Into the Renoprotective Effects of Combined N-Acetylcysteine and Glycine Treatment in Experimental Diabetic Nephropathy.Pharmacology research & perspectives · 2026Article
- Dual and context-dependent role of the interleukin-33/soluble suppression of tumorigenicity 2 axis in obesity and adipose tissue inflammation.Molecular medicine (Cambridge, Mass.) · 2026Article
- CD4Frontiers in immunology · 2026Review
- Therapeutic targets for diabetic nephropathy identified by druggable genome mendelian randomization: the role of the gut microbiota-metabolite axis.Frontiers in endocrinology · 2026Article
- Effect of pegagan (Narra J · 2024Article
- T cells and their products in diabetic kidney disease.Frontiers in immunology · 2023Review
- Molecular Mechanisms of Diabetic Kidney Disease.International journal of molecular sciences · 2022Review
- Bioinformatics analysis identifies diagnostic biomarkers and their correlation with immune infiltration in diabetic nephropathy.Annals of translational medicine · 2022Article
- The role of inflammation in diabetic kidney disease.The Korean journal of internal medicine · 2021Review
- Article
- 2-Deoxy-D-glucose Alleviates Collagen-Induced Arthritis of Rats and Is Accompanied by Metabolic Regulation of the Spleen and Liver.Frontiers in immunology · 2021Article
- Soluble Suppression of Tumorigenicity 2 is Directly Correlated with Glycated Hemoglobin in Individuals with an Average glycemia in the Normal/Prediabetes Range.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Association of Delta-6-Desaturase Expression with Aggressiveness of Cancer, Diabetes Mellitus, and Multiple Sclerosis: A Narrative ReviewAsian Pacific journal of cancer prevention : APJCP · 2019Review
- IL33/ST2 Axis in Diabetic Kidney Disease: A Literature Review.Medicina (Kaunas, Lithuania) · 2019Review
- Group 2 Innate Lymphoid Cells Participate in Renal Fibrosis in Diabetic Kidney Disease Partly via TGF-Journal of diabetes research · 2019Article
- IL-33 at the Crossroads of Metabolic Disorders and Immunity.Frontiers in endocrinology · 2019Review
- Intestinal Immunomodulatory Cells (T Lymphocytes): A Bridge between Gut Microbiota and Diabetes.Mediators of inflammation · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The role played by recently discovered novel cytokine IL-33 in controlling T-helper (Th)1 and Th2 cytokines under conditions of diabetic nephropathy (DN) is less well studied. In the present study, we estimated the levels of IL-33 along with both Th1 and Th2 cytokines in the serum of normal glucose tolerant (NGT), diabetic subjects with (DN) or without nephropathy (DM) and correlated it with the clinical risk factors of diabetes and nephropathy. 222 study subjects were recruited from the Chennai Urban Rural Epidemiology Study (CURES): 61 NGT, 79 DM and 82 DN. IL-33 level was estimated by ELISA while other Th1 (IL-12, IFN-gamma and IL-2) and Th2 (IL-4, IL-5 and IL-13) cytokines were measured using a Bio-plex bead assay. DM subjects showed a mixed Th1-Th2 profile (increased IFN-g, IL-12, IL-4 and IL-13 and decreased IL-33) while DN subjects showed enhanced Th1 profile (increased IFN-g, IL-2 and IL-12) with suppression of Th2 cytokine (decreased IL-33 and IL-13). The IL-33 levels showed a serial decline with increasing severity of insulin resistance and microalbuminuria. DN was associated with enhanced Th1 response and suppression of Th2 responses which might be due to inreased levels of IL-12 and decreased levels of IL-33 cytokines respectively.
Indexed as
Identifiers
25550844PMC4270517W2184942292What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.